Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. Actinium is developing innovative targeted radiotherapies for the treatment of advanced cancers.

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide an...
06/23/2025

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Read the press release: https://bit.ly/4jYVkX7

Actinium (NYSE: ATNM) Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of...
05/06/2025

Actinium (NYSE: ATNM) Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center.

Read the press release: https://bit.ly/3RQW8lu

Wrapping up an incredible ! Our team was pleased by the positive response to our posters on ATNM-400 and Actimab-A. A h...
04/29/2025

Wrapping up an incredible ! Our team was pleased by the positive response to our posters on ATNM-400 and Actimab-A. A huge thank you to the AACR community for the insightful discussions and interest. Stay tuned for more updates.

Both of our abstracts can be found here: https://ir.actiniumpharma.com/presentations-webinars

Actinium (NYSE: ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after P...
04/28/2025

Actinium (NYSE: ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting. Read the press release here: https://bit.ly/42NuI4P

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in...
04/28/2025

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the .

Read the press release here: https://bit.ly/42w85TG

Actinium is looking forward to presenting ATNM-400 data at today. The abstract includes results from in vitro and in v...
04/27/2025

Actinium is looking forward to presenting ATNM-400 data at today. The abstract includes results from in vitro and in vivo studies, including biodistribution imaging and efficacy analyses with various dose levels of ATNM-400. https://bit.ly/41OmjPt

Initial preclinical data from ATNM-400 will be presented at in Chicago on April 27, 2025, 2:00 pm – 5:00 pm CT. Highli...
04/21/2025

Initial preclinical data from ATNM-400 will be presented at in Chicago on April 27, 2025, 2:00 pm – 5:00 pm CT.

Highlights from the abstract include:

• ATNM-400 selectively binds to prostate cancer cells, undergoes rapid internalization, and induces dose-dependent cytotoxicity.
• In prostate cancer xenograft mouse models, ATNM-400 accumulated in tumors for up to 144 hours, while showing minimal uptake in normal tissues.
• Small animal SPECT/CT imaging with Indium-111-labeled antibody confirmed selective tumor accumulation and clearance from healthy tissues.
• A single dose of ATNM-400 achieved 68.5% tumor growth inhibition at 20 µCi/kg and 99.8% at 40 µCi/kg, with all doses being well tolerated.

ATNM-400 AACR Presentation Details:

• Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer
• Abstract Number: 578
• Session: PO.ET08.01 - Theranostics and Radiotheranostics
• Date & Time: April 27, 2025 – 2:00 pm – 5:00 pm CT

More details here: https://bit.ly/41OmjPt

Actinium Pharmaceuticals (NYSE: ATNM) Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radio...
03/27/2025

Actinium Pharmaceuticals (NYSE: ATNM) Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225.

Read more in our latest press release: https://bit.ly/41OmjPt

Actinium Pharmaceuticals (NYSE: ATNM) Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing No...
03/27/2025

Actinium Pharmaceuticals (NYSE: ATNM) Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives.

Read more in our latest press release: https://bit.ly/4ljYE14

Actinium Pharmaceuticals (NYSE: ATNM) to Present Business Update at Trump Mar-A-Lago Club Today. Read the press release ...
03/26/2025

Actinium Pharmaceuticals (NYSE: ATNM) to Present Business Update at Trump Mar-A-Lago Club Today.

Read the press release here: https://bit.ly/4j3Ntaz

Join Actinium’s KOL call and pipeline update featuring Dr. Ehab Atallah of the Medical College of Wisconsin today at 8:0...
03/25/2025

Join Actinium’s KOL call and pipeline update featuring Dr. Ehab Atallah of the Medical College of Wisconsin today at 8:00 AM ET.

He will discuss Actimab-A clinical results to date including recently published long-term survival outcomes and the planned pivotal Phase 2/3 clinical trial in r/r AML and trials to be conducted under Actinium's cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).

In addition, Actinium will provide a pipeline update to highlight 3 separate potential multi-billion-dollar blockbuster market opportunities for its targeted radiotherapies.

Register now: https://lifescievents.com/event/actinium-2/

Address

275 Madison Avenue, 7th Floor
New York, NY
10016

Website

Alerts

Be the first to know and let us send you an email when Actinium Pharmaceuticals, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Actinium Pharmaceuticals, Inc.:

Shortcuts

Share

Category